PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9358333

Adaptive survival trials.

W F Rosenberger·P Seshaiyer
View original source ↗Export metadata ↓

Abstract

We present a design for adaptive survival trials, where the probability of randomization to one of two treatments is skewed away from 0.5 according to the current value of the logrank statistic. A formula mapping the logrank statistic onto [0,1] is given, which is then used to bias a coin used for randomization. Simulation evidence shows that the allocation scheme works well and offers a more ethical alternative when lifetime data are available from other patients during the recruitment period. Power is not adversely affected by the resulting unequal allocation. The usual test statistic appears to be standard normal under the proposed allocation scheme.

Explore related subjects

Clinical Trials, Phase III as TopicComputer SimulationRandomized Controlled Trials as TopicResearch DesignStatistics as TopicSurvival RateJournal ArticleResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

W F Rosenberger, P Seshaiyer. 1997. Adaptive survival trials.. https://doi.org/10.1080/10543409708835211

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Squalene synthase inhibition: a novel target for the management of dyslipidemia.

A new class of compounds, known as squalene synthase inhibitors, has recently reached phase III clinical trials and may provide another therapeutic option for clinicians to improve risk management of low-density lipoprotein cholesterol (LDL-C). The clinical need for another LDL-C-lowering therapy is evident by the inability to achieve an LDL-C target of less than 70 mg/dL in the majority of very high-risk patients on statin monotherapy. Human clinical trial data with TAK-475, a novel and potent inhibitor of squalene synthase, have not yet been published.

Clinical Trials, Phase III as Topic↗
PubMed2006

[Herpes simplex virus vaccines: perspectives].

PURPOSE: Despite effective antiviral therapy, infection with herpes simplex virus (HSV) is a critical public health issue, particularly genital herpes by its social and psychological burden and its contribution to the neonatal herpes and possibly to the HIV/AIDS pandemic. CURRENT KNOWLEDGE: Many prophylactic and therapeutic vaccination approaches have been explored but no effective vaccine is presently available. In fact, as members of the Herpesviridae family, both HSV-1 and 2 types have genes involved in immune evasion. FUTURE PROSPECTS: Further research is needed to define determinants of immunity in order to design more effective vaccines.

Clinical Trials, Phase III as Topic↗